Curcumin has been recognized as an effective anticancer agent. However, due to its hydrophobic property, the cell absorption is not satisfied. Herein, the curcumin nanoparticles were prepared in the presence of polyethylene glycol 6000 (PEG6000) to reduce its elimination by immune system. For first time, not only the curcumin was encapsulated within the niosome nanoparticles modified by PEG, there are no reports related to the anticancer property of curcumin against thyroid cancers. The nanoparticles was developed and its anticancer was studied on sw-1736 cancer cell line. The nanoparticles were examined by scanning electron microscopy (SEM) and dynamic light scattering (DLS). Also, the release profile of curcumin, the IC50 concentration, the radical amount and the gene expression were evaluated. The optimized nanoparticles showed a diameter of 212 ± 31 nm by SEM and the encapsulation efficiency and loading capacity of 76% and 16.8% respectively. DLS confirmed the polydispersity index (PDI) of 0.596 and the release model was shown a sustained release with the delivery of 68% curcumin after 6 days. Also, the nanoparticles indicated the higher storage stability at 4 °C. After the cell treatment, the apoptotic bodies were appeared and IC50 was obtained as 0.159 mM. Moreover, the generated radicals by the treated cells was 86% after 72 h and the gene pattern indicated the bax/bcl2 ratio of 6.83 confirming the apoptosis effect of the nanoparticles. The results approved the nanoparticles could be suggested as an anticancer drug candidate for thyroid cancers.

姜黄素已被公认为有效的抗癌剂。然而，由于其疏水性，不能满足细胞吸收。在此，姜黄素纳米颗粒是在聚乙二醇 6000 (PEG6000) 存在下制备的，以减少免疫系统对姜黄素的消除。第一次，不仅姜黄素被包裹在经PEG修饰的纳米粒体中，还没有关于姜黄素对甲状腺癌的抗癌特性的报道。开发了纳米颗粒，并在 sw-1736 癌细胞系上研究了其抗癌作用。通过扫描电子显微镜（SEM）和动态光散射（DLS）检查纳米颗粒。此外，还评估了姜黄素的释放曲线、IC50 浓度、自由基量和基因表达。优化后的纳米粒子通过 SEM 显示直径为 212 ± 31 nm，封装效率和负载能力分别为 76% 和 16.8%。DLS 确认多分散指数 (PDI) 为 0.596，释放模型显示持续释放，6 天后释放 68% 姜黄素。此外，纳米颗粒在 4 °C 下表现出更高的储存稳定性。细胞处理后，出现凋亡小体，IC50为0.159 mM。此外，72 小时后处理细胞产生的自由基为 86%，基因模式表明 bax/bcl2 比率为 6.83，证实了纳米颗粒的细胞凋亡作用。结果表明，纳米粒子可以作为甲状腺癌的抗癌药物候选者。分别为 8%。DLS 确认多分散指数 (PDI) 为 0.596，释放模型显示持续释放，6 天后释放 68% 姜黄素。此外，纳米颗粒在 4 °C 下表现出更高的储存稳定性。细胞处理后，出现凋亡小体，IC50为0.159 mM。此外，72 小时后处理细胞产生的自由基为 86%，基因模式表明 bax/bcl2 比率为 6.83，证实了纳米颗粒的细胞凋亡作用。结果表明，纳米粒子可以作为甲状腺癌的抗癌药物候选者。分别为 8%。DLS 确认多分散指数 (PDI) 为 0.596，释放模型显示持续释放，6 天后释放 68% 姜黄素。此外，纳米颗粒在 4 °C 下表现出更高的储存稳定性。细胞处理后，出现凋亡小体，IC50为0.159 mM。此外，72 小时后处理细胞产生的自由基为 86%，基因模式表明 bax/bcl2 比率为 6.83，证实了纳米颗粒的细胞凋亡作用。结果表明，纳米粒子可以作为甲状腺癌的抗癌药物候选者。纳米粒子表明在 4°C 时具有更高的储存稳定性。细胞处理后，出现凋亡小体，IC50为0.159 mM。此外，72 小时后处理细胞产生的自由基为 86%，基因模式表明 bax/bcl2 比率为 6.83，证实了纳米颗粒的细胞凋亡作用。结果表明，纳米粒子可以作为甲状腺癌的抗癌药物候选者。纳米粒子表明在 4°C 时具有更高的储存稳定性。细胞处理后，出现凋亡小体，IC50为0.159 mM。此外，72 小时后处理细胞产生的自由基为 86%，基因模式表明 bax/bcl2 比率为 6.83，证实了纳米颗粒的细胞凋亡作用。结果表明，纳米粒子可以作为甲状腺癌的抗癌药物候选者。